Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)
National Institutes of Health (NIH)

Components of Participating Organizations
National Institute of Neurological Disorders and Stroke (NINDS)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute on Drug Abuse (NIDA)

National Institute of Nursing Research (NINR)

National Institute on Minority Health and Health Disparities (NIMHD)

National Center for Complementary and Integrative Health (NCCIH)

National Cancer Institute (NCI)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Behavioral and Social Sciences Research (OBSSR)

Funding Opportunity Title
HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
Activity Code
UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement
Announcement Type

Reissue of RFA NS-19-021

Related Notices

March 26, 2020 - NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19). See Notice NOT-OD-20-091.

February 6, 2020 - Notice of NIH Pre-Application Webinar for RFA-NS-20-028. See Notice NOT-NS-20-027.

July 26, 2019- Changes to NIH Requirements Regarding Proposed Human Fetal Tissue Research. See Notice NOT-OD-19-128

August 23, 2019- Clarifying Competing Application Instructions and Notice of Publication of Frequently Asked Questions (FAQs) Regarding Proposed Human Fetal Tissue Research. See Notice NOT-OD-19-137

Funding Opportunity Announcement (FOA) Number
RFA-NS-20-028
Companion Funding Opportunity

None

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.853, 93.213, 93.393, 93.273, 93.846, 93.279, 93.121, 93.307, 93.361

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications that propose clinical trials to test the comparative effectiveness of existing therapies for prevention or management of pain while reducing risk of addiction. Studies that inform providers and patients on best practices to manage acute or chronic pain in the primary care, emergency department, hospital or dental setting are priority areas of interest. The studies must evaluate methods and approaches to manage pain in these settings. Strategies might include safe use of medications, including appropriate use of opioids, biologics, devices or delivery systems, or multimodal approaches in controlled trials. Research testing behavioral interventions to manage pain will not be considered as high priority projects. The overall goal is to provide clinicians with robust evidence to best manage patients with acute or chronic pain in the primary care, emergency department, hospital or dental setting. Clinical trials will be conducted within the infrastructure of the HEAL Pain Effectiveness Research Network.

Key Dates

Posted Date

January 21, 2020

Open Date (Earliest Submission Date)
February 24, 2020
Letter of Intent Due Date(s)

30 days prior to the application due date

Application Due Date(s)

March 24, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s)

March 24, 2020.

All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Scientific Merit Review

June 2020

Advisory Council Review

October 2020

Earliest Start Date

October 2020

Expiration Date
New Date June 25, 2020 per Guide Notice NOT-OD-20-091. (Original Expiration Date:March 25, 2020 )
Due Dates for E.O. 12372
Not Applicable
Required Application Instructions
It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide,except where instructed to do otherwise (in this FOA or in a Notice from NIH Guide for Grants and Contracts ).

Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

  1. Use the NIH ASSIST system to prepare, submit and track your application online.
  2. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.

  3. Use Grants.gov Workspace to prepare and submit your application and eRA Commons to track your application.


  4. Table of Contents

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications that propose clinical trials to test the comparative effectiveness of existing therapies for prevention or management of pain while reducing risk of addiction. Studies that inform providers and patients on best practices to manage acute or chronic pain in the primary care, emergency department, hospital or dental setting are priority areas of interest. The studies must evaluate methods and approaches to manage pain in these settings. Strategies might include safe use of medications, including appropriate use of opioids, biologics, devices or delivery systems, or multimodal approaches in controlled trials. Research testing behavioral interventions to manage pain will not be considered as high priority projects. The overall goal is to provide clinicians with robust evidence to best manage patients with acute or chronic pain in the primary care, emergency department, hospital or dental setting. Clinical trials will be conducted within the infrastructure of the HEAL Pain Effectiveness Research Network. (HEAL Pain ERN), which was established through the infrastructure of the National Center for Advancing Translation Sciences (NCATS) Trial Innovation Network (TIN). Trials will be implemented at the Clinical and Translation Science Award (CTSA) Program hubs, which each may contain multiple clinical sites at different institutions, and/or any other clinical sites selected by the investigator that is not affiliated with the CTSA program.

Awards made under this FOA will support a milestone-driven planning phase (UG3) for 1 year, with possible transition to a clinical trial implementation phase (UH3) of up to an additional four years. Only UG3 projects that meet the scientific milestones and feasibility requirements will transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. This FOA may NOT be used for applications that propose testing of interventions to establish initial efficacy of drugs, devices or biologics for approval by the Food and Drug Administration (FDA).

Background

This multisite effectiveness research consortium is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. This broad research effort seeks to improve pain care through understanding the development of chronic pain and by accelerating and improving the process of therapy development to more rapidly move discoveries into clinical practice to alleviate the burden of pain. More information about the HEAL Initiative is available at: https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative.

Public Law 115-141, the Consolidated Appropriations Act of 2018 (signed March 23, 2018) includes a requirement that grantees from for-profit applicant organizations must provide a 50% match and/or in-kind contribution of all federally awarded dollars under the grant award (direct costs, as well as facilities and administrative costs) for research related to opioid addiction, development of opioid alternatives, pain management and addiction treatment.

Matching Requirement: A grantee from a for-profit organization funded under this funding opportunity announcement must match funds or provide documented in-kind contributions at a rate of not less than 50% of the total-Federally awarded amount, as stipulated by Public Law 115-141, the Consolidated Appropriations Act of 2018.The applicant will be required to demonstrate that matching funds and/or in-kind contributions are committed or available at the time of, and for the duration of, the award. Applications must identify the source and amount of funds proposed to meet the matching requirement and how the value for in-kind contributions was determined. All matching funds and/or in-kind contributions must be used for the portion of allowable project costs not paid by Federal funds under the grant award. NIH will not be the recipient, nor serve as a pass-through entity, of any such matching funds and/or in-kind contributions required under this announcement. See 45 CFR 75.306 for additional details.

The Nation faces a crisis of high prevalence of chronic pain and associated opioid use disorder and overdose deaths. More than 50 million adults in the U.S. have experienced chronic pain, and over 25 million report pain every day. Nearly 20 million U.S. adults report high-impact chronic pain, which is defined as pain that interferes with their life. Many groups report a relatively high prevalence of chronic pain and high-impact chronic pain including women, older adults, previously but not currently employed adults, adults living in poverty, adults with public health insurance, and rural residents (2016 National Health Interview Survey data).

Reducing the burden of pain nationwide is a significant unmet need, and individuals need safe, non-addictive treatments to alleviate pain or methods to manage opioid use in a safe and effective manner. Severe pain often is associated with diseases and chronic conditions such as diabetes, cancer, endometriosis, and sickle cell disease, and it may persist as chronic pain following many surgical procedures or trauma. Chronic pain conditions such as complex regional pain syndrome, migraine, and fibromyalgia are diseases themselves, and many chronic pain conditions co-occur in individuals. The strength of evidence for the effectiveness of current strategies currently used to manage pain is often low to moderate (CDC Guideline for Prescribing Opioids for Chronic Pain). These strategies include some non-pharmacologic treatments for specific chronic pain conditions, long-term opioid therapy and different methods to initiate and titrate opioids, and comparisons of non-opioid and opioid drugs for pain management. More studies also are needed to inform evidence-based non-opioid treatments in the peri-operative setting.

Research Interests Specific to this FOA

This FOA is soliciting applications for clinical “effectiveness” research for management of pain in ways that reduce the risk of addiction. Effectiveness research is defined as the conduct and synthesis of research comparing the benefits and harms of different interventions and strategies to prevent, treat and monitor pain conditions in “real world” settings. The purpose of this research is to improve functional health outcomes by developing and disseminating evidence-based information to patients, clinicians, and other decision-makers, responding to their expressed needs, about which interventions are most effective for which patients under specific circumstances. To provide this information, comparative effectiveness pain research must assess a comprehensive array of health-related outcomes for diverse patient populations and subgroups.

Modified from Source: https://osp.od.nih.gov/wp-content/uploads/FCCCER-Report-to-the-President-and-Congress-2009.pdf

Most pain management is delivered in the primary care settings where providers have few evidence-based guidelines to support their clinical decisions. Acute pain management often is delivered in emergency departments, hospital settings or dental clinics where reliance on treatment with opioids increases risks for Opioid Use Disorder (OUD). Adults with pain due to injury, neck and back pain, abdominal pain or headache make up over 33 million ER visits per year. Evidence for best pain care practices in these settings are lacking. In addition, quality, precision pain care following surgical or other procedures with medications including opioids and other pharmacological therapies and devices needs a more robust evidence base to guide providers in these settings, would promote tailored acute pain care, and reduce reliance on opioids. Therefore, the overall goal of this FOA is to provide clinicians with robust evidence to best manage patients with acute or chronic pain in the primary care, emergency department, hospital or dental setting. Research results should inform clinicians about best practices to manage or prevent pain with medications, devices, or appropriate multimodal strategies.

Research Objectives

This FOA will prioritize the following areas of interest to generate evidence-based pain management best practices for treatment strategies in the primary care, emergency department, hospital or dental setting in use of existing medications or devices for specific pain conditions. The following are high priority research areas:

  • acute and chronic pain management in primary care, emergency rooms, hospitals, and dental clinics;
  • chronic overlapping pain conditions;
  • best practices for effective analgesics when appropriate;
  • pain management in individuals at risk of or with OUD;
  • pain management in those with co-occurring mental health disorders; and
  • Non cancer pain management in persons with medical comorbidities.

Research testing behavioral interventions to manage pain will not be considered as high priority projects since several currently funded HEAL trials are testing behavioral interventions for pain management. Investigators wishing to test the effectiveness of behavioral interventions should contact program officials from individual ICs to find an appropriate FOA. Research testing software or decision-making tools that help providers and patients determine the most effective and safe methods for pharmacological or device pain management are allowed.

Applicants should review the NIH HEAL website at https://heal.nih.gov/funding/awarded and the Patient-Centered Outcomes Research Institute website https://www.pcori.org/research-results to avoid submitting a trial that overlaps significantly with other on-going trials testing methods to manage pain.

This FOA may NOT be used for applications that propose testing of interventions to establish initial efficacy of drugs, devices or biologics for approval by the FDA (see instead other opportunities such as EPPIC-Net below). Applicants interested in conducting such trials are encouraged to contact an NIH Program Official of the scientifically appropriate NIH Institute or Center to discuss other FOAs for this purpose. Non-responsive applications will be withdrawn.

Opportunities to Submit other Types of Pain Clinical Trials:

For further information on these programs see: https://www.painconsortium.nih.gov/Funding_Research/Funding_Opportunities

The Early Phase Pain Investigation Clinical Network (EPPIC-Net) will provide infrastructure for the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain. This network will support exploratory clinical trials of investigational drugs and biologics, investigational devices, natural products, and surgical procedures for the treatment of pain. These trials may include deep phenotyping, validation of biomarkers and proof of mechanism, to support justification and provide the data for designing a future Phase 3 trial. The specific pain conditions of interest for EPPIC-Net include well-defined conditions with high unmet therapeutic needs in patients across the lifespan.

The Pragmatic and Implementation Studies for the Management of Pain (PRISM) program will support studies to integrate interventions that have demonstrated efficacy into health care systems or implement health care system changes to improve adherence to evidence-based pain management guidelines. PRISM encourages cooperative research applications to conduct efficient, large-scale pragmatic trial or implementation science study designs to improve pain management. The program requires that the intervention under study be embedded into health care delivery system, real world settings. The pragmatic trial model collects most data needed for analysis of the research question as part of clinical care, and it is expected that this data will be obtained primarily through the electronic records of the health care system. Studies needing to randomize participants individually, collect in-person measures for research purposes (such as specified clinical laboratory tests, observed studies of mobility or other measures of function) or deliver an intervention in a standardized fashion should consider applying to the HEAL Pain Management Effectiveness Research Network (HEAL Pain ERN).

It is expected that trials in the HEAL Pain ERN will recruit women in sufficient numbers to determine sex-specific responses as well as sex differences in trial outcomes. These comparisons have significant clinical relevance given the higher prevalence of pain in women. Studies should, as appropriate, enroll both sexes to better understand the influence of sex as a variable.

Overview of the HEAL Pain ERN Network

Awardees will be required to conduct their studies through the NIH HEAL Pain ERN which has dedicated pain and clinical trial design expertise. The HEAL Pain ERN will use the infrastructure of the NCATS Trial Innovation Network (TIN) (www.trialinnovationnetwork.org ) to provide scientific guidance and coordination of the HEAL Pain ERN trials. The TIN works with the broad consortium of Clinical and Translational Science Awards (CTSA) hubs (https://ctsa.ncats.nih.gov/ ) that each may contain multiple clinical sites at different institutions, to implement studies. Points of contact (POC) for the HEAL Pain ERN at the individual CTSA hubs will be posted on www.trialinnovationnetwork.org . TIN dedicated pain and trial experts will participate on study teams of awarded UG3/UH3 projects during the planning and implementation phases and will provide clinical coordination center (CCC) services, data coordination center (DCC) services, recruitment and retention services, and biostatistical support for the UH3 trials.

The HEAL Pain Management Clinical Effectiveness Research Program Overview

Pain experts and clinical trial experts from the HEAL Pain ERN CCC, DCC, and biostatistics core, NIH staff, and the awardees investigative team (PIs, biostatistician and study coordinator) will serve as the Clinical Trial Steering Committee, one for each trial, and will work collaboratively to plan and implement the trials. A consortium of all the Clinical Trial Steering Committees across all funded trials – defined here as the Program Steering Committee - will convene yearly in person or by conference call. The individual Clinical Trial Steering Committees will meet regularly throughout the duration of the implementation phase of the trials.

Specific functions provided by the HEAL Pain ERN CCC, DCC and biostatistical core include:

  • Developing the final study protocol with the study team investigators;
  • Providing study design support and independent statistical analysis of the primary trial results; and interpretation of results for manuscripts and publications;
  • Finalizing recruitment and retention plans with the site investigators before initiation of the trial;
  • Developing associated trial documents, including the Manual of Procedure or Standard Operating Procedures; materials for site investigators, case report forms and training materials for study personnel with the study team;
  • Training clinical site investigators and staff for the individual trials. Training areas include, but are not limited to, regulatory requirements, Good Clinical Practice (GCP), adverse event reporting, human subject protections, informed consent, and NIH policies and procedures;
  • Developing and maintaining a data management system for trial data collection and storage and adverse event reporting;
  • Providing randomization support;
  • Providing clinical operations and monitoring support including project management, to oversee and coordinate activities associated with the clinical trials, study implementation, from study start-up through additional site selection as needed, enrollment, site management, study monitoring and close out. This includes assistance finding additional CTSA hub sites if needed in the UG3 and UH3 phase to meet enrollment goals.
  • Monitoring enrollment and retention at the individual sites and working with sites that fail to meet their enrollment targets;
  • Preparing reports for the Data and Safety Monitoring Boards;
  • Providing single IRB services for the trial;
  • Working with the awardees to execute the Master Clinical Trial Agreement to the individual clinical sites, and
  • Providing logistics for face to face meetings of the cooperatives’ investigators.

Applicants should make note of the following:

Applicants should propose their primary outcome based on that most appropriate for the trial question. Standardized pain measures and functional outcomes are strongly encouraged to ensure that data is translatable across all HEAL initiative pain studies. Secondary outcomes, including selected patient reported outcomes related to pain, addiction, and selected pain and associated measures, will be added to the protocol during the UG3 development phase. A final list of these required measures will be developed during the FY2020 planning year collaboratively by the Program Steering Committee and additional experts as appropriate.

The award and continuation of funding are subject to milestones to be specified in the notice of grant award. At the time of an award, the PD(s)/PI(s), TIN personnel, and NIH staff will negotiate the scope and study development activity timeline for UG3 award and implementation activity timeline for the UH3 award. The project work scope and timeline will include identifying the primary individual or entity and other contributors responsible for study development, start-up and implementation activities, and the timeline for completion of these activities.

Applications that do not include milestones will be considered non-responsive to this FOA and will not be reviewed (see section below: Milestones and UG3/UH3 Transition)

NIH is developing guidance for collection of common data elements and data harmonization across HEAL and HEAL related clinical pain studies. The guidance is applicable to this FOA.

Applicants should include letters of intent to participate from sites named in the application, whether they be within and outside the CTSA consortium.

NIH Resources: As appropriate, applicants are encouraged to make use of the following resources for clinical research including:

(a) Clinical and Translational Science Award (CTSA) program https://nacts.nih.gov/ctsa ;

(b) NIH Toolbox (http://www.nihtoolbox.org );

(c) PROMIS (http://www.nihpromis.org ); and

(d) NINDS Common Data Elements (http://www.commondataelements.ninds.nih.gov ).

Scope of the UG3/UH3 FOA

Each UG3/UH3 Clinical Trial Implementation Cooperative Agreement application can propose the planning and implementation of only one clinical trial.

NIH is interested in supporting clinical trials that are designed to answer questions based on a strong scientific premise and are carried out through a robust approach. To adequately plan and finalize the details for implementation of the clinical trials, investigators, in coordination with the CCC and DCC, and NIH staff, need time to prepare. Therefore, the UG3 component of the award will support a one-year planning phase during which limited funds will be awarded. Applicants and recipients of UG3 funding should note that the UG3 award does not guarantee subsequent UH3 funding for implementation of the clinical trial. Only those trials that successfully meet the scientific milestones and feasibility requirements for transition will be funded to move to the trial implementation phase (UH3).

Clinical Trial Planning Phase (UG3)

The UG3 award supports the planning period and is not intended for the collection of preliminary data (neither clinical nor pre-clinical studies) about the efficacy or effectiveness of an intervention, or the collection of prospective data to support the rationale for a clinical trial. During this year, the awardees, as part of the Clinical Trial Steering Committee will develop their protocols and associated study documents.

After awards are made, the awardees will assess and refine the study design and statistical analysis collaboratively through the Clinical Trial Steering Committee. NIH Program staff will ensure that sets of common data elements are collected and used appropriately in the studies to ensure translation of shared data across HEAL supported clinical studies.

Examples of study documents that will be developed with the TIN CCC, DCC and biostatistical core during the UG3 phase include, but are not limited to:

  • A final clinical protocol developed in cooperation with the CCC, DCC and biostatistical core following International Conference on Harmonization (ICH) E6 Good Clinical Practice Consolidated Guidance, prepared using the standard interventional protocol template that will provided by the HEAL Pain ERN;
  • The Manual of Procedures (MOP), developed in collaboration with the HEAL Pain ERN DCC and study site investigators including a detailed description of study procedures and process details;
  • Staff training and recruitment plans in collaboration with the CCC and Recruitment Innovation Center;
  • The final statistical analysis plan, which will be developed in collaboration with the HEAL Pain ERN biostatistical core;
  • The electronic data capture system, that will be developed and maintained by the TIN DCC as the central HEAL Pain ERN data capture system;
  • The consent form(s) or, if applicable, permission and assent form(s), which will be developed with assistance from the HEAL Pain ERN CCC and DCC;
  • Safety standards and regulatory processes;
  • Plans for biospecimen collection (if appropriate to the study) and storage protocols;
  • A plan for the administration of study agent(s), if applicable;
  • Detailed description of Roles and Responsibilities of study personnel developed in conjunction with the HEAL Pain ERN CCC;
  • The final quality management and data management plans developed with the HEAL Pain ERN CCC and DCC; and
  • Strategies to put in place should enrollment or retention not meet specified metrics.

The final protocol must be accepted by NIH and receive approval by the single IRB and the Data and Safety Monitoring Boards (DSMBs) overseeing the individual trials. In addition, each site must agree to use a Master Clinical Trial Agreement that will be provided by the HEAL Pain ERN CCC, which serves as a one-time contract for participation in a HEAL Pain ERN study, and are expected to use a single Institutional Review Board (sIRB).

Clinical Trial Implementation Phase (UH3):

The planning year will be followed by up to four additional years of higher funding levels, during which the study will be implemented. The objective of the up to 4-year UH3 implementation phase is to conduct the clinical trial in accordance with activities planned in the UG3 phase. The trial outcome measure(s) must be clinically meaningful and important to stakeholders including patients and health care providers. The NIH expects clinical trials supported during the UH3 phase to be hypothesis driven, milestone-defined, and have the potential for high impact within the research mission of the HEAL Pain initiative. The clinical trial must meet all applicable NIH, Food and Drug Administration (FDA), and Office of Human Research Protections (OHRP) policy requirements.

Milestones and UG3/UH3 Transition

Applications must include well-defined milestones for the planning phase (UG3) and annual milestones for the clinical trial implementation phase (UH3). Prior to a pending award, the PD/PI and NIH will negotiate a final list of milestones for each year of support. The proposed milestones for the UH3 phase may be revised during the award period in coordination with NIH staff, the CCC and DCC, as activities in the UG3 phase progress.

At the completion of the UG3 planning phase or sooner if possible, the applicant will be required to submit a detailed transition proposal for the UH3 clinical trial implementation phase. The UH3 transition proposal will undergo an administrative review to determine whether the study will be awarded the implementation phase (UH3). The review will determine if the UG3 planning milestones named in the “Milestone Plan” have been met, and that the UH3 phase can successfully test the chosen hypothesis in a timely fashion.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument
Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.
Application Types Allowed
New

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.

Clinical Trial?
Required: Only accepting applications that propose clinical trial(s)

Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

NIH intends to fund an estimate of one to two awards, corresponding to a total of $800,000 for fiscal year 2020 and a total of $2,000,000 per year for fiscal year 2021, 2022, 2023 and 2024. Future year amounts will depend on annual appropriations.

Award Budget

Budgets may not exceed $500,000 in direct costs for the UG3 year and $1,000,000 in direct costs for the UH3 years. The Trial Innovation Network will provide infrastructure including the data management system, clinical coordination, and monitoring. These trial infrastructure costs should not be included in the UG3/UH3 budgets.

Award Project Period

The scope of the proposed project should determine the project period. The required project period for the UG3 phase is one year, and the maximum project period for the UH3 phase is four years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions

  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

  • Hispanic-serving Institutions
  • Historically Black Colleges and Universities (HBCUs)
  • Tribally Controlled Colleges and Universities (TCCUs)
  • Alaska Native and Native Hawaiian Serving Institutions
  • Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)

Governments

  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • Indian/Native American Tribal Governments (Federally Recognized)
  • Indian/Native American Tribal Governments (Other than Federally Recognized)
  • Eligible Agencies of the Federal Government
  • U.S. Territory or Possession
Other
  • Independent School Districts
  • Public Housing Authorities/Indian Housing Authorities
  • Native American Tribal Organizations (other than Federally recognized tribal governments)
  • Faith-based or Community-based Organizations
  • Regional Organizations
Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. 

Required Registrations

Applicant organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

  • Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
  • System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
  • eRA Commons - Applicants must have an active DUNS number to register in eRA Commons.Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration, but all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
  • Grants.gov – Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Eligible Individuals (Program Director/Principal Investigator)
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

3. Additional Information on Eligibility

 

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101)

Section IV. Application and Submission Information

1. Requesting an Application Package

The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guideexcept where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

 

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

  • Descriptive title of proposed activity
  • Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
  • Names of other key personnel
  • Participating institution(s)
  • Number and title of this funding opportunity

The letter of intent should be sent to:

Linda Porter, Ph.D.

Telephone: 301-435-7572

Email: porterl@ninds.nih.gov

Page Limitations
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed
Instructions for Application Submission
The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.
SF424(R&R) Cover
All instructions in the SF424 (R&R) Application Guide must be followed.
SF424(R&R) Project/Performance Site Locations
All instructions in the SF424 (R&R) Application Guide must be followed.
SF424(R&R) Other Project Information
All instructions in the SF424 (R&R) Application Guide must be followed.
SF424(R&R) Senior/Key Person Profile
All instructions in the SF424 (R&R) Application Guide must be followed.
 

All instructions in the SF424 (R&R) Application Guide must be followed.

Costs not to include:

The budget should not contain costs for Clinical Coordinating Center, the Data Coordinating Center or a data management system. These will be supplied through core funding.

Costs for single IRB review will be supplied through core funding if the applicant uses a Trial Innovation Network single IRB.

Costs to include:

  • Costs to clinical sites for screening, enrollment and evaluation of participants or costs such as core laboratory costs, biospecimen shipping costs or costs for acquiring study agents should be included in the applicant’s budget as study costs.
  • Costs at the clinical sites, budgeted on a per-subject or per-procedure basis. Applicants should provide a breakdown of the total per subject costs as part of the budget justification and should indicate how the cost for an item or procedure was determined.
  • Costs for collection, analysis, storage, and shipping of biospecimens during the study duration should be included as a separate item in the budget. Specimens collected beyond those needed for the study or remaining at the close of study will be shipped and stored in the NIH HEAL common repository. Applicants are encouraged to provide specimens to the central HEAL repository for future access. Costs for shipping to the repository should be included in the budget. Costs for long-term storage in the HEAL repository will be covered through other HEAL funds.
  • Applicants should budget for the investigator team to travel to a face to face annual one-day, in-person-within study investigator meeting, and applicants should budget to allow up to 6 persons from the investigator team to attend. (The expenses of the meeting room rental will be covered by NIH.) If some trial costs are to be borne by sources other than NIH, these contributions must be presented in detail in the budget justification. These costs borne by third parties do not constitute cost-sharing as defined in the current NIH Grants Policy Statement and should not be presented as part of the requested budget.
R&R Subaward Budget
All instructions in the SF424 (R&R) Application Guide must be followed.
PHS 398 Cover Page Supplement
All instructions in the SF424 (R&R) Application Guide must be followed.
PHS 398 Research Plan
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:

Significance and Clinical Relevance: Describe the significance of the proposed effectiveness clinical trial in the context of establishing the benefits of pharmacological or device interventions for pain management and the risks and benefits of the proposed study interventions. Discuss how the trial will test the hypotheses proposed and how the results of the trial (positive or negative) will advance the field and inform guidelines. Applicants are encouraged to include evidence such as letters or references that relevant stakeholders (e.g. potential subjects, referring and treating physicians, patient organizations, or professional organizations) view the question to be important.

Previous Studies: Present the major findings of the previous efficacy clinical studies that led to the proposed effectiveness trial. Ensure that the data supporting the proposed trial meet the NIH scientific rigor guidelines (seehttps://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-103.html). Data supporting efficacy of the proposed intervention may come from the applicant’s previous work or from published literature.

Investigator(s): Describe the expertise of the study team in the conduct of multi-center trials, the team’s ability to plan and implement the proposed study, and the investigator’s experience working cooperatively with a consortium that includes a central CCC and DCC without duplicating information in the biosketches.

Approach:

The approach should clearly justify the clinical relevance for the length of observation for the pain outcome and the additional outcomes such as adverse effects associated with treatment. Do not duplicate information described in the Study Record: PHS Human Subjects and Clinical Trials Information form.

The Approach section should have a clear demarcation of the UG3 and UH3 portions of the application.

For the UG3 phase:

  • Describe the study development activities outlined in the UG3 Milestone Plan in the PHS Human Subjects and Clinical Trials Information Form planned for the UG3 phase, including a plan to meet the milestones.

For the UH3 phase, include the following:

  • An assessment of the feasibility of recruiting participants who are eligible for the proposed research.
  • An overview of the proposed study design that must justify the selected trial elements provided in the Protocol Synopsis, including:
  • Rationale for the selected trial design and allocation method.
  • Rationale for selection of the intervention to be tested and a description of how and at what dosing and frequency the intervention will be administered.
  • Justification for selection of the primary and secondary outcome measures and a description of how the outcome variables will be collected and the criteria for measuring the outcomes. Applicants should allow flexibility in determining the secondary outcome measures pending NIH determinations of Common Data Elements.
  • Description of the study population, including the pain condition or pain state, sample size, pertinent demographic information, required health status, and geographic location. Justify why the study population is an appropriate group to address the study objectives. Do not duplicate information described in Section 2 (Study Population Characteristics) of the Study Record: PHS Human Subjects and Clinical Trials Information form.
  • Discuss potential biases or challenges in the proposed trial and how they will be minimized and/or addressed.
  • Describe the study activities outlined in the UH3 Milestone Plan in the PHS Human Subjects and Clinical Trials Information Form and how the milestones will be met.

Letters of Support

For-profit applicants must include a letter(s) of support confirming that the required secured cost matching (cash; in-kind commitments such as salary, consultant costs, equipment) is available and confirm that the essential personnel have the authority within the organization to allocate resources.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

The following modifications also apply:

All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan that is consistent with the NIH HEAL Initiative Public Access and Data Sharing Policy. See https://heal.nih.gov/about/public-access-data .

Appendix:
Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
PHS Human Subjects and Clinical Trials Information
When involving human subjects research, clinical research, and/or NIH-definedclinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Section 2 - Study Population Characteristics

2.5 Recruitment and Retention Plan

Applicants should state how many sites will be needed and survey the potential clinical sites to ensure that recruitment targets can be met. A list of HEAL CTSA points of contact will be posted on www.trialinnovationnetwork.org.

Include a description of how additional sites not named in the application (Clinical and Translational Science award (CTSA) Program hubs sites or any other investigator-selected sites) will be selected and used as clinical sites to implement the trial. Specify the criteria for selecting additional sites. Existing other network clinical sites suitable to answer the study question may also be used, but the other network must use the TIN DCC and CCC and participate in all HEAL Pain ERN activities.

The plan should also include a contingency plan for adding new sites if enrollment falls behind targets or discontinuing enrollment of new participants at sites that do not meet individual goals.

Section 3 - Protection and Monitoring Plans

3.2 Single Institutional Review Board (sIRB)

It is expected awardees will use a single Institutional Review Board (sIRB) to conduct the ethical review required by HHS regulations for the Protections of Human Subjects Research unless review by the proposed sIRB would be prohibited by a federal, tribal, or state law, regulation, or policy. For this FOA, the three Trial Innovation Network (TIN) Single IRBs are available to serve as the sIRB of record. If the awardee elects to use these sIRBs, the assignment will be made post award. There is no need to request the services. For more information about the Single IRBs affiliated with the TIN, see

https://trialinnovationnetwork.org/elements/central-irb/

3.3 Data and Safety Monitoring Plan

It is expected that a Data and Safety Monitoring Board (DSMB) will oversee each trial, consistent with the policy of the IC managing the trial. Applicants should refer to the specific guidelines of the Institute or Center with a scientific interest in the proposed trial to guide development of their Data and Safety Monitoring Plan (DSMP). The final DSMP will be developed with the managing IC after award. For IC specific DSMB policies see https://www.painconsortium.nih.gov/Funding_Research/Funding_Opportunities

A Clinical Site Monitoring Plan will be developed with the Clinical Trial Steering Committee during the first year of the study. This plan will include how site adherence to the protocol and consenting process will be ensured, who is responsible for site monitoring, the frequency of planned monitoring activities and the plan for handling deficiencies, or closure of sites. Plans for training and, if needed, certifying site personnel to complete study procedures will be developed by the PD/PI and HEAL Pain ERN DCC and CCC during the UG3 phase of the study.

A detailed Data Management Plan, including the methods and systems for data collection and quality control, and for ensuring data confidentiality and privacy, and the process for locking the final dataset will be developed by the HEAL Pain ERN DCC and the PD/PI during the UG3 phase of the study.

Describe the plans, if any, to use non-traditional data collection approaches (e.g., digital/mobile/sensor technologies and web-based systems) and why these are appropriate.

Section 4 - Protocol Synopsis

4.4 Statistical Design and Power

Applicants should provide a Statistical Analysis Plan (SAP) including details about the power analysis used to determine how the study sample size was determined, analyses specified in the study protocol, including a description of how the statistical analysis of the primary, secondary and other endpoints will be performed, how missing data will be handled, plans for interim analyses for safety and futility, plans for recalculation of the sample size midway through the trial (if applicable), etc. If computer simulations were used to investigate the operating characteristics of complex clinical trial designs (such as adaptive designs), to choose between alternative outcome measures, or to determine sample size, accounting for the impact of noncompliance, missing data, subject eligibility criteria, etc., sufficient details about the simulations should be provided if the SAP. It is particularly important to discuss the range of conditions that were considered in the simulation and why this range was considered appropriate, how robust the findings were across the range of conditions considered, and how the study will adjust for any design deficiencies (e.g., bias, loss of power) the simulations revealed.

The final SAP will be developed with statisticians from the TIN biostatistics core. There must be a plan for an independent biostatistician to analyze study results according to the prespecified statistical analysis plan.

4.6 Will the study use an FDA-regulated intervention?

This FOA will not support studies of interventions of investigational products under IND or IDE.

4.7 Dissemination Plan

UG3/UH3 applicants must submit a plan for the dissemination of NIH-funded clinical trial information that will address how the expectations of the NIH Policy on the Dissemination of NIH-funded Clinical Trial Information will be met. Responsibility for adhering to this policy lies with the UG3/UH3 grantee institution, not with the TIN Coordinating Center awardees.

Section 5 – Other Clinical Trial-related Attachments

5.1 Other Clinical Trial-related Attachments

Additional Instructions: The information provided here will be considered by reviewers and is meant to supplement, not duplicate, information provided in the Research Plan or other sections of the PHS Human Subjects and Clinical Trials Information form. The following documents must be uploaded as separate pdf files with the names indicated below.

Schedule of Events. The filename "Schedule of Events" should be used to name this attachment. If multiple attachments are needed, amend the file name accordingly (e.g., Schedule of Events 1, Schedule of Events 2, etc.). Provide a schematic, table, or text description of the protocol-specified schedule of events for an individual study participant. It should capture each study visit/assessment time point and planned activity(ies) for each time point.

Milestone Plan. The filename "Milestone Plan" should be used to name this attachment. If multiple attachments are needed, amend the file name accordingly (e.g., Schedule of Events 1, Schedule of Events 2, etc.).

The Milestone Plan must describe separate milestones for the UG3 and UH3 phases.

Applicants are required to provide detailed project performance and timeline objectives. This attachment must include two sections: those milestones to be completed during the UG3 planning phase and those to be completed during the UH3 phase. The plan should present an overview of the project timeline to achieve the following general milestones, as applicable:

Milestones to be completed during the UG3 phase:

  • Finalization of plans to obtain study agent(s), if applicable;
  • Finalization of clinical sites, demonstration that the necessary study population is available at the clinical sites, and finalization of plans to add or drop clinical sites if needed;
  • Finalization of agreements for use of resources available within CTSAs, practice-based research networks, patient registries, etc.;
  • Finalization of clinical protocol;
  • Regulatory approvals (IRB and applicable oversight committees);
  • Finalization of all documents necessary to implement the trial, such as case report forms;
  • Registration of clinical trial in ClinicalTrials.gov; and
  • Participation in consortium and common data elements process.

Milestones to be completed during the UH3 phase:

  • Site activation;
  • Enrollment of the first subject;
  • Enrollment and randomization, if applicable, of 25%, 50%, 75% and 100% of the projected study population;
  • Any planned interim analyses;
  • Completion of data collection time period;
  • Completion of primary endpoint and secondary endpoint data analyses;
  • Completion of final study report; and
  • Reporting of results in ClinicalTrials.gov per the NIH policy on Dissemination of NIH-Funded Clinical Trial Information.
  • Milestones and timelines will be refined and finalized in consultation with Program staff at the time of award.

Applications that lack the Milestone Plan attachment are considered nonresponsive and will not be reviewed.

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.

PHS Assignment Request Form
All instructions in the SF424 (R&R) Application Guide must be followed.

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times

Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

Post Submission Materials
Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the policy.

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.

Overall Impact
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Scored Review Criteria
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

 

Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial needed to advance scientific understanding?

Does the application provide evidence that relevant stakeholders (e.g. potential subjects, referring and treating physicians, patient groups) view the question to be important?

Is there adequate data supporting efficacy of the proposed intervention to warrant an effectiveness trial for the selected outcome(s) in the proposed population?

Are the results from the proposed trial likely to inform evidence-based guidelines for management of acute or chronic pain in ways that would reduce the risk of addiction?

 

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?

 

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?

 

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

Does the application adequately address the following, if applicable

Study Design

Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?

Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex/gender and race/ethnicity?

Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?

Data Management and Statistical Analysis

Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?

Are pain outcomes from participants collected for a period that is clinically meaningful to inform clinical decision making?

Does the application adequately address the following:

UG3 Planning Phase

Are there clear plans to obtain any study agents? Are there clear plans to work in collaboration with the DCC and CCC for developing a final clinical protocol and associated documents? Are there appropriate plans for the final selection of the clinical sites and necessary populations for the future study? Is there an adequate discussion of potential challenges that are anticipated during planning and study implementation, and how they will be addressed? Is there evidence of how the investigators will work with the consortium to finalize the UH3 study plans? Is the plan appropriate?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?

 

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed?

Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate?

If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?

Additional Review Criteria
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

Study Timeline

Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate?

Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?

M?ilestones?

Are appropriate, evaluative milestones clearly defined for the UG3 phase, and is it likely that the investigator team will meet these milestones within the proposed project period?

Are appropriate, evaluative milestones clearly defined for the UH3 phase? Are the milestones feasible and quantifiable with regard to specific aims and timeline?

 

For research that involves human subjects but does not involve one of thecategories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

 

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

 

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

 

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

 

Not Applicable.

 

Not Applicable.

 

Not Applicable.
Additional Review Considerations
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

 

Not Applicable.

 

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

 

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3) Genomic Data Sharing Plan (GDS).

 

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

 

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review (CSR), in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications:
  • May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
  • Will receive a written critique.
Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:
  • Scientific and technical merit of the proposed project as determined by scientific peer review.
  • Availability of funds.
  • Relevance of the proposed project to program priorities.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

Section VI. Award Administration Information

1. Award Notices

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.

Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.

Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.

ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain “applicable clinical trials” on the ClinicalTrials.gov Protocol Registration and Results System Information Website (https://register.clinicaltrials.gov). NIH expects registration and results reporting of all trials whether required under the law or not. For more information, see https://grants.nih.gov/policy/clinical-trials/reporting/index.htm

Institutional Review Board or Independent Ethics Committee Approval: Grantee institutions must ensure that all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the awardee must provide NIH copies of documents related to all major changes in the status of ongoing protocols.

Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).

Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person’s race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 “Federal awarding agency review of risk posed by applicants.” This provision will apply to all NIH grants and cooperative agreements except fellowships.

For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/index.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see https://www.hhs.gov/civil-rights/for-individuals/section-1557/index.htmlhttps://www.hhs.gov/civil-rights/for-providers/laws-regulations-guidance/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see https://www.hhs.gov/civil-rights/for-individuals/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.htmlor call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.

Cooperative Agreement Terms and Conditions of Award

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Part 75, and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for the HEAL PAIN ERN program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below. Awardee will retain custody of and have primary rights to the data and software developed under this award, subject to Government rights of access consistent with current DHHS, PHS, and NIH policies.

The PD(s)/PI(s) will have the primary responsibility for:

  • Determining research approaches, designing protocols with the PD/PIs of the HEAL Pain ERN CCC and biostats core, setting project milestones, and conducting research. The awardee agrees to accept close coordination, cooperation, and participation of NIH staff in those aspects of scientific and technical management of the study as stated in these terms and conditions.
  • Implementation of the protocol, each study, whether a single entity or a consortium of entities, and following the procedures required by the protocol regarding study conduct and monitoring, participant management, data collection, and quality control.
  • Participating in group activities, including the Program Steering Committee, the Clinical Trial Steering Committee, and subcommittees as needed.
  • The Program Steering Committee, which will meet in person once and three additional times by teleconference during the planning year. The Clinical Trial Steering Committees will meet regularly throughout the during of the study. The Program Steering Committee will recommend the frequency of other in-person and teleconference meetings as needed.
  • Providing reports and data in a timely fashion as agreed upon by the HEAL Pain ERN Program Steering Committee.
  • Submitting all data as soon as they are collected to the HEAL Pain ERN DCC for quality control.
  • Preparing abstracts, presentations and publications and collaborating Consortium-wide in making the public and professionals aware of the program.
  • Assessing and disseminating data and methods developed for or derived from the HEAL Pain ERN program within and outside the Consortium.
  • Adhering to policies regarding data sharing and publication established by the NIH and the HEAL Pain ERN Program Steering Committee.
  • Abiding by common definitions, protocols, and procedures, as determined in collaboration with the Program Steering Committee.
  • Submitting periodic progress reports in a standard format, as agreed upon by the Program Steering Committee and Clinical Trial Steering Committees.
  • Attending and participating in HEAL Pain ERN Program and Clinical Trial Steering Committee meetings and accepting and implementing decisions by these groups, as appropriate.
  • The PD(s)/PI(s) will manage involvement of industry or any other third party in the study. Except for licensing of patents or copyrights, support or involvement of any third party will occur only following notification of and concurrence by the NIH.

NIH staff will have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

The NIH Project Scientist(s) will have substantial scientific and programmatic involvement during the conduct of this activity through technical assistance, advice, and coordination. The Project Scientist(s) will participate as members of the HEAL Pain ERN Program Steering Committee and the Project Scientists together will have a single vote. The Project Scientist(s) will have the following substantial involvement:

  • Participating through the HEAL Pain ERN Program Steering Committee in addressing issues that arise with HEAL Pain ERN planning, operation, assessment, and data analysis. The Project Scientist(s) will assist and facilitate the group process and not direct it.
  • Serving as a liaison, helping to coordinate activities, including acting as a liaison to other NIH Institutes/Centers, and as an information resource for the awardees. The Project Scientist(s) will also help coordinate the efforts of the HEAL Pain ERN Program with other groups conducting similar efforts.
  • Attending all HEAL Pain ERN Program Steering Committee meetings as a voting member, assisting in developing standard operating procedures, and consistent policies for dealing with situations that require coordinated action. The Project Scientist(s) will be responsible for working with the awardees as needed to manage the logistic aspects of the HEAL Pain ERN program.
  • Reporting periodically on HEAL Pain ERN progress to the NIH Leadership.
  • Serving on subcommittees of the HEAL Pain ERN Program Steering Committee as appropriate.
  • Assisting awardees in the development, if needed, of policies for dealing with situations that require coordinated action.
  • Providing advice in the management and technical performance of the award.
  • Assisting in promoting the availability of the data and related resources developed in the course of this program to the scientific community at large.
  • Participating as appropriate in co-authorship of the publication of results of studies conducted through the program, consistent with the policies of their ICO.

In addition, an agency Program Official or IC Program Director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice. The assigned Program Official may also serve as an NIH Working Group Project Scientist(s) to assist the awardee. Prior to funding an application, the Program Official will contact the applicant to discuss the proposed milestones and any changes suggested by NIH staff or the NIH review panel. The Program Official and Project Scientist will negotiate with the applicant and agree on a final set of approved milestones which will be specified in the Notice of Award. The NIH Program Official, in consultation with the Project Scientist and NIH HEAL Pain ERN Working Group, will determine if the awardee has met the milestones required for each year of funding.

NIH reserves the right to withhold funding or curtail an award in the event of:

  • Substantive changes in the project, or failure to make sufficient progress toward the work scope with which NIH concurred, or
  • Ethical or conflict of interest issues.

Areas of Joint Responsibility include:

Close interaction among the participating investigators will be required, as well as significant involvement from the NIH, to manage, assess, and implement the HEAL Pain ERN program. The awardees and the Project Scientist(s) will meet through the HEAL Pain ERN Program Steering Committee times during the planning year, and through the Clinical Trials Steering Committees regularly over subsequent years, and on conference calls as needed to share information on methodologies, analytical tools, and preliminary results. PDs/PIs, key co-investigators and pre- and post-doctoral trainees, especially those who are members of under-represented minority groups or those from different but related disciplines, are eligible to attend these meetings.

The HEAL Pain ERN Program Steering Committee will be responsible for coordinating the activities conducted by the program and is the committee through which the individual NIH HEAL Pain ERN Clinical Trials Steering committees will formally interact. The HEAL Pain ERN Program Steering Committee membership will include PD(s)/PI(s) of each HEAL Pain ERN award, other staff as needed, the NIH Project Scientist(s) and the dedicated pain and clinical trial experts from the CCC, DCC, and biostatistics core. The HEAL Pain ERN Program Steering Committee may add additional members, and other government staff may attend the HEAL Pain ERN Program Steering Committee meetings as desired.

The HEAL Pain ERN Program Steering Committee may establish subcommittees as needed to address particular issues, which will include representatives from the program and the NIH and possibly other experts. The HEAL Pain ERN Program Steering Committee will have the overall responsibility of assessing and prioritizing the progress of the various subcommittees.

The HEAL Pain ERN awardee agrees to work collaboratively to:

  • Provide for secure, accurate and timely data submission.
  • Participate in presenting and publishing new processes and substantive findings.
  • Assess and disseminate HEAL Pain ERN data and resources.
  • Interact with other relevant NIH activities, as needed, to promote synergy and consistency among similar projects.

Dispute Resolution:

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. The three members will be: a designee of the HEAL PAIN ERN Program Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.

3. Reporting

When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.
A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreementsare required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM)about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings.Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 – Award Term and Conditions for Recipient Integrity and Performance Matters.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
Application Submission Contacts
eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threatensubmission by the due date, and post-submission issues)

Finding Help Online:http://grants.nih.gov/support/(preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email:GrantsInfo@nih.gov(preferred method of contact)
Telephone: 301-945-7573

Grants.gov Customer Support(Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email:support@grants.gov

Scientific/Research Contact(s)

Linda L. Porter, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-435-7572
Email: porterl@ninds.nih.gov

Jane C. Atkinson, DDS
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-827-6031
Email: jatkinso@mail.nih.gov

Lanay Mudd, PhD
National Center for Complementary and Integrative Health (NCCIH)
Telephone: 301-594-9346
Email: lanay.mudd@nih.gov

Alexis Bakos, PhD, MPH, RN
National Cancer Institute (NCI)
Telephone: 240-276-6609
Email: alexis.bakos@nih.gov

Soundar Regunathan, PhD
National Institute on Alcohol Abuse and Alcoholism National Institutes of Health (NIAAA)
Telephone: 301-443-1192
Email: soundar.regunathan@nih.gov

Chuck Washabaugh, PhD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Telephone: 301-594-5055
Email: washabac@mail.nih.gov

Susan Marden, PhD, RN
National Center for Medical Rehabilitation Research
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-435-6838
Email: mardens@mail.nih.gov

Will M. Aklin, Ph.D.
National Institute on Drug Abuse
Telephone: 301.827.5909
Email:aklinwm@nida.nih.gov

Dena Fischer, DDS, MSD, MS
National Institute of Dental and Craniofacial Research (NIDCR)
Telephone: 301-594-4876
Email:dena.fischer@nih.gov

Matthew Rudorfer, PhD
National Institute of Mental Health (NIMH)
Telephone: 301-443-1111
Email: ?mrudorfe@mail.nih.gov

Benyam Hailu, MD, MPH
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-8696
Email: ?benyam.hailu@nih.gov

Jeremy Brown, MD
National Institute for Neurological Disorders and Stroke (NINDS)
Telephone: 301-827-8375
Email: Jeremy.brown@nih.gov

Lois A. Tully, PhD
National Institute of Nursing Research (NINR)
Telephone: 301-594-5968
Email: tullyla@mail.nih.gov

Peer Review Contact(s)

J?oseph Rudolph, PhD
Center for Scientific Review (CSR)
Telephone: 301-408-9098
Email: josephru@mail.nih.gov

Financial/Grants Management Contact(s)

Stacia Fleisher
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-435-0851
Email: stacia.fleisher@nih.gov

Shelley Carow
National Center for Complementary and Integrative Health (NCCIH)
Telephone: 301-594-3788
Email: carows@mail.nih.gov

Diana Rutberg, MBA
National Institute of Dental and Craniofacial Research (NIDCR)
Telephone: 301-594-4798
Email: rutbergd@mail.nih.gov

Chief Grants Management Officer
National Institute of Neurological Disorders and Stroke (NINDS)
Email: ChiefGrantsManagementOfficer@ninds.nih.gov

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Authority and Regulations
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
NIH Office of Extramural Research Logo
Department of Health and Human Services (HHS) - Home Page
Department of Health
and Human Services (HHS)
USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.